Drug Information

Drug General Information
Drug ID
D02BQE
Former ID
DNCL002615
Drug Name
E7820
Drug Type
Small molecular drug
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 2 [531326]
Company
Eisai
Structure
Download
2D MOL

3D MOL
Formula
C17H12N4O2S
Canonical SMILES
CC1=C2C(=CNC2=C(C=C1)NS(=O)(=O)C3=CC=CC(=C3)C#N)C#N
InChI
1S/C17H12N4O2S/c1-11-5-6-15(17-16(11)13(9-19)10-20-17)21-24(22,23)14-4-2-3-12(7-14)8-18/h2-7,10,20-21H,1H3
InChIKey
LWGUASZLXHYWIV-UHFFFAOYSA-N
PubChem Compound ID
196970
PubChem Substance ID
10262229, 14851274, 33516962, 48426303, 52322289, 58107227, 113464178, 126453583, 126659356, 135174033, 172918937, 198940922, 224077676, 227776242, 247750450, 249814522, 252215328
Target and Pathway
Target(s) Integrin alpha-2 Target Info Inhibitor [531326]
KEGG Pathway Phagosome
PI3K-Akt signaling pathway
Focal adhesion
ECM-receptor interaction
Platelet activation
Hematopoietic cell lineage
Regulation of actin cytoskeleton
Pathways in cancer
Proteoglycans in cancer
Small cell lung cancer
Hypertrophic cardiomyopathy (HCM)
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
Dilated cardiomyopathy
NetPath Pathway IL4 Signaling Pathway
EGFR1 Signaling Pathway
PANTHER Pathway Integrin signalling pathway
Pathway Interaction Database Beta1 integrin cell surface interactions
Integrin family cell surface interactions
Arf6 trafficking events
CXCR4-mediated signaling events
Plexin-D1 Signaling
Syndecan-2-mediated signaling events
VEGFR3 signaling in lymphatic endothelium
Reactome Integrin cell surface interactions
Laminin interactions
Syndecan interactions
ECM proteoglycans
CHL1 interactions
Platelet Adhesion to exposed collagen
WikiPathways TGF beta Signaling Pathway
Focal Adhesion
Human Complement System
Extracellular matrix organization
Interleukin-11 Signaling Pathway
Arrhythmogenic Right Ventricular Cardiomyopathy
miR-targeted genes in muscle cell - TarBase
miR-targeted genes in lymphocytes - TarBase
Platelet Adhesion to exposed collagen
Integrin-mediated Cell Adhesion
L1CAM interactions
Integrin cell surface interactions
References
Ref 531326Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies. Clin Cancer Res. 2011 Jan 1;17(1):193-200.
Ref 531326Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies. Clin Cancer Res. 2011 Jan 1;17(1):193-200.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.